1190861-43-8

Basic information

• Product Name: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE
• Synonyms: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE;6-bromospiro[1H-indole-3,4'-oxane]-2-one;6-Bromo-1H-spiro[indole-3,4'-oxane]-2-one
• CAS NO: 1190861-43-8
• Molecular Formula: C₁₂H₁₂BrNO₂
• Molecular Weight: 282.13318
• Mol File: 1190861-43-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 437.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.61±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.70±0.20(Predicted)
• CAS DataBase Reference: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE(1190861-43-8)
• EPA Substance Registry System: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE(1190861-43-8)

Safety Data

• Hazardous Substances Data: 1190861-43-8(Hazardous Substances Data)

Usage

General Description

6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one is a chemical compound with a spirocyclic structure, containing a bromine atom and a pyran ring. It is commonly used as a building block in the synthesis of various pharmaceuticals and bioactive compounds due to its unique structural properties. 6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one has been found to exhibit potential biological activities, including antifungal, antibacterial, and anticancer properties. Its spirocyclic structure also makes it a valuable scaffold for the design of new drug candidates. Additionally, it has been studied for its potential use in the treatment of neurological disorders and as an anti-inflammatory agent. Further research is ongoing to explore the full range of potential applications for this compound in the field of drug development and medicinal chemistry.

Upstream product

• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 99365-40-9 6-bromo-2,3-dihydro-1H-indole-2-one 
• 100487-82-9 4-bromo-2-nitro-benzoic acid methyl ester 
• 34270-90-1 2,2'-diiodoethyl ether 
• 1202765-53-4 methyl 4-(4-bromo-2-nitrophenyl)tetrahydro-2H-pyran-4-carboxylate 
• 1190861-47-2 tert-butyl 6-bromo-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-1-carboxylate 
• 100487-81-8 2-(4-bromo-2-nitro-phenyl)malonic acid dimethyl ester 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 

Downstream Products

• 1202765-56-7 6-bromo-2',3',5',6'-tetrahydrospiro[dihydroindole-3,4'-pyran] 
• 1190859-96-1 N-Cyclopropyl-4-methyl-3-(2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-6-yl)benzamide 
• 1190859-98-3 N-Isoxazol-3-yl-4-methyl-3-(2-oxo-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-pyran]-6-yl)benzamide 
• 1259513-65-9 1-(3-methyl-2-phenyl-4-quinolinyl)-6-(4-morpholinyl)-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-pyran] 

Relevant articles and documents

Preparation Method for Amide Compounds and Use Thereof in Medical Field

Provided are a preparation method for amide compounds and use thereof in medical field. Specifically, provided are small molecule amide compounds. Such compounds are inhibitors of enhancer homolog 2 (EZH2) of Zeste gene, and can be used for preventing and/or treating related diseases mediated by EZH2, including tumors, myeloproliferative diseases or autoimmune diseases.

Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors

Structure-based rational design led to the synthesis of a novel series of potent PI3K inhibitors. The optimized pyrrolopyridine analogue 63 was a potent and selective PI3Kβ/δ dual inhibitor that displayed suitable physicochemical properties and pharmacokinetic profile for animal studies. Analogue 63 was found to be efficacious in animal models of inflammation including a keyhole limpet hemocyanin (KLH) study and a collagen-induced arthritis (CIA) disease model of rheumatoid arthritis. These studies highlight the potential therapeutic value of inhibiting both the PI3Kβ and δ isoforms in the treatment of a number of inflammatory diseases.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.